Title : Personalized and Precision Medicine (PPM) as a unique healthcare model via design-driven bio- and chemical engineering view of biotech
Abstract:
A new healthcare-related systems approach resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). In this sense, despite breakthroughs in research, the translation of discoveries into therapies for patients has not kept pace with healthcare need. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc. The latter delves into the selection of bioremediation strategies, highlighting the critical role of harmonizing nature's mechanisms with PPM-guided engineering. It explores the design and optimization of bioremediation systems, emphasizing reactor design, process control, and resource efficiency. Bio-designers, bioengineers and chemical engineers, bio-manufacturers and biomarket experts are beginning to realize the promise of PPM, translating to direct benefit to patients or persons-at-risk. Moreover, chemical and biological engineers are now using OMICS tools and the knowledge gained with them to tackle grand challenges facing society – such as the need for new medicines to fight disease and prevent pandemics, and the barriers preventing expansion of modern biomanufacturing across the world. And across worldwide research and throughout the bioindustries, scientific breakthroughs have been the launching point for principal bioproduct developments in the translational trajectory.
At bio- and chemical engineering being co-partnered to make biotech upgraded, we are working hard on issues affecting society where chemistry and its applied subareas play a crucial role. And the integrated skills of bio- and chemical engineers are uniquely suited to developing next-generation solutions to persistent health challenges. In this context, the healthcare bioindustry is focused on improving the quality of medical treatments by developing minimally invasive techniques for diagnosis and including with the help of new advances in the field of nanotechnology-driven bio- and chemical engineering. The latter are becoming an introduction to upgraded aspects of biotech, which will be the concern of the bio- and/or chemical engineer, with an emphasis on design tasks. In this sense, scaling up from a laboratory reaction to a bioindustrial process is the main challenge for bio- and chemical engineers. This is a complicated optimization problem at many levels: environmental impact, intellectual and transdisciplinary resources and cost must be minimized and the quality and process safety maximized. And strategic alliances and the collaborative work in this area already includes initiatives with polymeric biomaterials, nucleic acids, microfluidics and other tools that offer valuable information at the cellular and molecular levels to develop a more tailored and personalized approach. Of particular interest is design-driven nanotechnology research at the biointerface, including nanoparticles developed to detect pre-early cancer biomarkers; ‘smart surfaces’ mimicking conditions in the body and encouraging high rates of stem cell production; and the engineering of cells to produce the building blocks. Bio- and chemical engineering integrate basic science, mathematics, and engineering principles in a coherent manner that equips the engineers to tackle a remarkable variety of challenges. So, partnering and forming strategic alliances between researchers, bio-designers, bio- and chemical engineers, clinicians, business, regulatory bodies and government can help ensure an optimal development program that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets. Co-development between innovation-related builders and customers is a key agile principle. And biotech is becoming as much an exciting part of design-driven bio- and chemical engineering today as it is promising for its future. And in the coming wave of innovation in the broad-scope applications, learning rapidly what new bioproduct features work well for clinicians and patients will become even more crucial.
